SRI-22136 / Southern Research - LARVOL DELTA

Development of Delta Opioid Receptor Antagonists Which Prevent Alzheimer's Disease-Like Pathology in the 5X-Familial Alzheimer's Disease [5XFAD] Mouse Model. (PubMed, ACS Pharmacol Transl Sci) - "We identified a lead compound 12 (SRI-22136) with sub-nM DOR potency, high selectivity, and high inhibition of β-secretase activity...This treatment completely prevented Alzheimer's-like pathology, including memory deficits, β-secretase activity, Aβ1-42 accumulation, and brain inflammatory markers. Together these results suggest 12 as a potential new lead compound to prevent Alzheimer's Disease."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders

Development of Novel Delta Opioid Receptor (DOR) Antagonist for the Treatment of Alzheimer’s Disease (Neuroscience 2024) - "Also, in our brain histological analysis the compound exhibited greater efficacy in reduction of the AD pathology markers such as Aβ and inflammatory markers GFAP (astrocytes) and CD11b (microglia) in AD transgenic mice. These results suggest that SRI-22136 and similar DOR antagonists could be novel therapies for the treatment of AD."

Alzheimer's Disease • CNS Disorders • Dementia • GFAP • ITGAM

Sri 22136, a novel delta opioid receptor (dor) antagonist for the treatment of alzheimer's disease (Neuroscience 2022) - "Further the compound exhibited greater reduction in biochemical marker such as BACE-1 and Aβ using the cortex and hippocampus regions of the APP/PS AD model double-transgenic mice. These results suggest that SRI-22136 and similar DOR antagonists could be novel therapies for the treatment of AD."

Alzheimer's Disease • CNS Disorders • Dementia • GFAP • ITGAM